Einerseits verhindern die Pharma-Multis die Publikation wichtiger Forschungsergebnisse …
To a doctor reading the published literature, 94% of the trials conducted were positive. In reality, 51% were positive.
Quelle: EzraKlein Archive | The American Prospect
… andererseits nehmen sie viel Geld in die Finger und üben unterbewusst Einfluss auf die Einstellung der Forschenden aus:
A recent survey found that about two thirds of academic medical centers hold equity interest in companies that sponsor research within the same institution. A study of medical school department chairs found that two thirds received departmental income from drug companies and three fifths received personal income.
Beängstigend. Wie eine zu starke Interessenbindung an den Auftraggeber so richtig schief gehen kann, zeigt das Debakel um die Rating-Firmen und deren Bewertung von Ramsch-Hypotheken.
